Duration of Short-Course Androgen Suppression Therapy and the Risk of Death As a Result of Prostate Cancer

We evaluated whether the duration of androgen suppression therapy (AST) had an impact on the risk of prostate cancer-specific mortality (PCSM) in men with unfavorable-risk prostate cancer (PC) within established Gleason score (GS) categories. Between February 2, 1996, and December 27, 2001, 761 men...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 2011-12, Vol.29 (35), p.4682-4687
Hauptverfasser:	D'AMICO, Anthony V, CHEN, Ming-Hui, CROOK, Juanita, ARMSTRONG, John G, MALONE, Shawn, STEIGLER, Allison, DUNNE, Mary, KANTOFF, Philip W, DENHAM, James W
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Androgen Antagonists - therapeutic use Antineoplastic Agents, Hormonal - therapeutic use Biological and medical sciences Cohort Studies Combined Modality Therapy Humans Male Medical sciences Neoplasm Staging Nephrology. Urinary tract diseases ORIGINAL REPORTS Prognosis Prostatic Neoplasms - drug therapy Prostatic Neoplasms - pathology Prostatic Neoplasms - radiotherapy Treatment Outcome Tumors Tumors of the urinary system Urinary tract. Prostate gland
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!